Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: SUSE5A | ISIN: LU2333210958 | Ticker-Symbol: N/A
Frankfurt
13.11.23
08:01 Uhr
10,670 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
SUSE SA Chart 1 Jahr
GlobeNewswire (Europe)
169 Leser
Artikel bewerten:
(1)

SUSE LLC: SUSE AI Gives Control, Privacy, and Trust to Enterprises Implementing Open Source AI Solutions

Finanznachrichten News

Tata Consultancy Services (TCS) working with SUSE AI for security, extensibility and flexibility that customers need.

SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- SUSE®, a global leader in innovative, open and secure enterprise-grade solutions, today announced availability of SUSE AI, a secure, trusted platform to deploy and run GenAI applications. Delivered as an integrated cloud native solution, SUSE AI comes with built-in flexibility and extensibility. SUSE AI unlocks industry leading large language models (LLMs) and helps companies retain full control of AI Solutions, empowered with choice and sovereignty.

As enterprises move from the AI experimentation phase to deployment, security and compliance pose a significant roadblock to fully realizing AI's potential. Most AI solutions are not designed with privacy in mind so organizations in highly regulated industries like finance or industries who need to protect their original IP must painstakingly create their own AI solution-a slow, complex, and time-consuming process. SUSE AI addresses these challenges by enabling enterprises to easily run private GenAI solutions, maintaining security without sacrificing the speed and power of AI solutions.

SUSE AI was built with the input of SUSE's AI Early Access Program, a collaborative initiative bringing together customers and partners with SUSE's GenAI experts to provide the basis for secure and compliant generative AI in the enterprise.

"AI is incredibly powerful, but without consideration, it has the potential to cause harm and damage reputations. As the value of GenAI - and the need for it - becomes more apparent, we are seeing customers struggle with compliance risks, shadow AI, and a lack of control, not to mention the vendor lock-in and skyrocketing costs associated with early-stage AI solutions," said Abhinav Puri, Vice President of Portfolio Solutions at SUSE. "SUSE's approach to AI, delivered in our SUSE AI solutions and the SUSE AI Early Access Program, helps address these issues for customers."

Nidhi Srivastava, Global Head of AI.Cloud Offerings, TCS, said, "As enterprises demand for more secure, scalable AI solutions, our customers look to us for help in solving their critical challenges in privacy, compliance, and control. We are thrilled to partner with SUSE on the launch of its SUSE AI platform. Its new GenAI capabilities help to maintain security and sovereignty, which is essential in today's regulatory landscape. Together with SUSE, we are committed to helping enterprises use AI to drive meaningful innovation while keeping their data protected."

Benefits of SUSE AI include:

  • Secure by design: SUSE AI provides security and certifications at the software infrastructure level and tools that provide zero trust security, templates and playbooks for compliance. With SUSE AI, they can ensure that all use and processing of sensitive and private data remains private, significantly reducing the risk of data breaches and any unauthorized access. SUSE AI components are built with SUSE's common criteria certified build system, which sanitizes the software and performs vulnerability scans. This ensures the security and integrity of those components and can reduce the impact of security breaches with enhanced incident response and recovery efforts.
  • Multifaceted trust: With SUSE AI, customers can trust their AI solutions - trust the security of the platform, trust that the generated data is correct and trust that their private customer and IP data stay private. They can deploy well-managed AI wherever their business needs it, from on-premise to hybrid to cloud and even in air-gapped environments. Enterprises can future-proof by taking advantage of the AI components provided as part of SUSE AI or bring their own AI tools to accommodate their unique use cases and increased workloads.
  • Choice: SUSE AI provides choice to customers by providing a secure platform on which they can select any AI components. Customers have full control over platform optimization and extension as well as flexibility in selecting and deploying large language models (LLMs). Simplified cluster operations and persistent storage along with easy access to pre-configured shared tools and services mean customers can rely on SUSE AI under any circumstance.

SUSE AI launched as part of SUSE's presence at KubeCon North America 2024 in Salt Lake City Nov. 12-15. To learn more, visit http://www.suse.com/products/aior read the blog.

About SUSE
SUSE is a global leader in innovative, reliable and secure enterprise open source solutions, including SUSE? Linux Suite, SUSE? Rancher Suite, SUSE? Edge Suite and SUSE? AI Suite. More than 60% of the Fortune 500 rely on SUSE to power their mission-critical workloads, enabling them to innovate everywhere - from the data center to the cloud, to the edge and beyond. SUSE puts the "open" back in open source, collaborating with partners and communities to give customers the agility to tackle innovation challenges today and the freedom to evolve their strategy and solutions tomorrow. For more information, visit www.suse.com.

Media Contact
rachel.romoff@suse.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.